Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
uprifosbuvir + grazoprevir + ruzasvir
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is an investigational, oral, fixed-dose combination of three direct acting antivirals for the treatment of chronic hepatitis C virus (HCV) infection. The regimen includes uprifosbuvir, a uridine nucleotide analog inhibitor of HCV NS5B polymerase; grazoprevrir, an HCV NS3/4A protease inhibitor; and ruzasvrir, a pangenotypic HCV NS5A inhibitor. Together, these agents target multiple steps in the viral replication cycle to achieve sustained virologic response across various HCV genotypes. Developed by Merck & Co., this combination demonstrated high efficacy and good tolerability in clinical trials for multiple HCV genotypes but was ultimately discontinued from further development[1][2][4][6].
- Brand names
- MK-3682BMK3682BMK 3682B
- Other names
- grazoprevir + uprifosbuvir + ruzasvir
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on uprifosbuvir + grazoprevir + ruzasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on uprifosbuvir + grazoprevir + ruzasvir.